Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr
The company reported a standalone net profit of ₹99.3 crore for FY26, up from ₹52.6 crore, and proposed a final dividend of ₹10 per share.
— 3 earlier stories on Venus Remedies Ltd. →What's new
- Standalone net profit rose to ₹99.3 crore from ₹52.6 crore in FY25.
- Revenue from operations grew 19% to ₹768.7 crore.
- The board recommended a final dividend of ₹10 per share.
Why this matters
Profit growth significantly outpaced revenue gains, suggesting improved margins and operational efficiency. The dividend declaration signals management's confidence in the company's cash flow position after a year of strong bottom-line expansion.
What we're watching
- Consolidated performance metrics compared to standalone results.
- Shareholder approval for the proposed ₹10 dividend.
- Sustainability of margin improvements in the coming fiscal year.
The full read
Venus Remedies delivered a strong finish to FY26, with standalone net profit climbing 89% to ₹99.3 crore from ₹52.6 crore a year earlier. Revenue from operations rose 19% to ₹768.7 crore, indicating that the company successfully expanded its margins alongside its top-line growth. On a consolidated basis, the profit growth was even more pronounced at 127%. The board has proposed a final dividend of ₹10 per share, pending shareholder approval. This performance reflects a clear improvement in operational efficiency. The company is now in a position to reward shareholders while maintaining a trajectory of profit expansion that significantly outstrips its revenue growth.
Questions answered
- How much did Venus Remedies earn in FY26?
- The company reported a standalone profit after tax of ₹99.3 crore for the financial year ended March 2026, compared to ₹52.6 crore in the previous year.
- What was the revenue growth for the year?
- Revenue from operations reached ₹768.7 crore, representing a 19% increase over the prior year.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹10 per share, which remains subject to approval by shareholders.
- Did consolidated results show similar growth?
- Yes, consolidated profit growth was even higher at 127% year-on-year.
Venus Remedies Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on VENUSREM →- 26 May 2026 · 9:54 PM IST Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr
- 46d ago Venus Remedies reports audited results and declares dividend
- 46d ago Venus Remedies posts 89% profit jump and names new board members
- 50d ago Venus Remedies gets first global approval for oncology drug in Saudi Arabia